Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bacterial membranes and enzymes encompass a diverse array of structural components and catalytic proteins essential for the viability and proliferation of bacterial pathogens. The cell membrane serves as a critical semi-permeable barrier and a scaffold for bioenergetic processes, while bacterial enzymes facilitate vital functions such as peptidoglycan synthesis, DNA replication, and protein translation (StatPearls, 2023). These targets are the foundation of modern antibiotic therapy; for instance, beta-lactams target penicillin-binding proteins to inhibit cell wall synthesis, while polymyxins disrupt the integrity of the outer membrane in Gram-negative bacteria (NIH, 2022). Because many of these targets are unique to prokaryotes or differ significantly from eukaryotic homologs, they offer a high degree of selective toxicity, minimizing damage to human cells. However, the clinical utility of drugs hitting these targets is increasingly compromised by the emergence of multi-drug resistant strains, which employ mechanisms like target modification, efflux pumps, or enzymatic degradation of the drugs (Nature Reviews Microbiology, 2017). Understanding the interplay between these membranes and enzymes is crucial for developing next-generation antimicrobials to combat global infectious disease threats.
Antibiotics targeting these components act through several distinct mechanisms: inhibition of cell wall biosynthesis by targeting penicillin-binding proteins (e.g., beta-lactams) or peptidoglycan precursors (e.g., glycopeptides); disruption of the cytoplasmic or outer membrane integrity (e.g., lipopeptides, polymyxins); inhibition of protein synthesis by binding to the 30S or 50S ribosomal subunits (e.g., aminoglycosides, macrolides); and interference with nucleic acid synthesis by inhibiting DNA gyrase/topoisomerase IV or RNA polymerase (e.g., fluoroquinolones, rifamycins).
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial cell membrane and enzymes.